ECE2015 Eposter Presentations Diabetes (complications & therapy) (143 abstracts)
Lixisenatide clinical experience on patients with type 2 diabetes and obesity in Endocrinology Offices
M Mar Roca-Rodríguez 1 , María Teresa Muros de Fuentes 2 , Gonzalo Piédrola-Maroto 2 , Miguel Quesada-Charneco 3 , Silvia Maraver-Selfa 1 , M José Tapia-Guerrero 1 , Daniel Cepero-García 4 , Rosa Orduña-Espinosa 3 , Joaquín Pechuán-Asensio 5 , Elena Ferrándiz-Millón 4 , Purificación Galera-Martínez 2 , Mercedes Vázquez-Gutiérrez 4 & Isabel Mancha-Doblas 1
1Department of Endocrinology, Virgen de la Victoria and Regional Hospitals, Malaga, Spain; 2Department of Endocrinology, Virgen de las Nieves Hospital, Granada, Spain; 3Department of Endocrinology, San Cecilio Hospital, Granada, Spain; 4Department of Endocrinology, Torrecardenas Hospital, Almeria, Spain; 5Endocrinology Private Office, Granada, Spain.
Introduction: Some treatments of diabetes, such as lixisenatide, improve global metabolic status beyond glycaemic control.
Aim: To evaluate tolerance to lixisenatide and its effects on weight and metabolic control in type 2 diabetes and obese patients attended in Endocrinology Offices.
Material and method: A prospective study of patients with type 2 diabetes and obesity. In an intra-subject analysis, clinical and analytical data were evaluated at baseline and after lixisenatide treatment.
Results: We studied 104 patients (51% women) with type 2 diabetes and obesity. Average age was 58.4±10.5 years, average duration of diabetes was 11.2±6.7 years, and 35.6 and 69.6% had family history of cardiovascular disease and diabetes respectively. At baseline, 92.2% of the patients had oral hypoglycaemic agents, 13.5% GLP1 agonists and 67.3% insulin (44.2% basal insulin, 12.5% premixed insulin, and 10.6% basal-bolus insulin). We re-evaluated the patients 3.8±1.6 months after treatment with lixisenatide. We found significant improvements in weight (P<0.001), BMI (P<0.001), WC (P=0.002), SBP (P<0.001), DBP (P=0.001), fasting glucose (P≤0.001), HbA1c (P=0.022), total-chol (P<0.001), LDL-chol (P=0.046), TG (P=0.020), hypertension drugs (P<0.001), and lipids drugs (P<0.001). We checked that blood pressure and lipid improvement were not due to hypertension and lipid treatment intensification. No changes in levels of amylase related to lixisenatide treatment were observed. Regarding digestive tolerance to lixisenatide, 7.9% of patients did not tolerate, 5% tolerated 10 μg/day, and 85.1% tolerated 20 μg/day.
Conclusions: Significant improvement of anthropometric parameters and glycaemic control in terms of fasting glucose and HbA1c, and significant decrease of blood pressure and lipid profile were observed. Lixisenatide was safety and well tolerated in most patients. In addition, we found a significant intensification of antihypertensive and lipid-lowering therapy, not only hypoglycaemic, in our clinical practice with an overall metabolic approach of patients.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more